menu search

Day One Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Progress

Day One Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Progress
First patient dosed in pivotal Phase 3 FIREFLY-2/LOGGIC trial evaluating tovorafenib (DAY101) as a frontline therapy for patients newly diagnosed with pediatric low-grade glioma (pLGG) Reported topline data in January 2023 from ongoing, pivotal Phase 2 FIREFLY-1 trial demonstrating meaningful responses with tovorafenib (DAY101) in relapsed or progressive pLGG Additional data from FIREFLY-1 planned for […] The post Day One Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate... Read More
Posted: Mar 6 2023, 21:30
Author Name: forextv
Views: 101977

Search within

Pages Search Results: